Brief: Ascletis Pharma Says US FDA Cleared IND Application For Oral Small Molecule IL-17 Inhibitor, ASC50
22/05/2025 11:25
May 22 (Reuters) - Ascletis Pharma Inc 1672.HK: U.S. FDA CLEARANCE OF IND APPLICATION FOR ORAL SMALL MOLECULE IL-17 INHIBITOR, ASC50 Further company coverage: 1672.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026